UNSPSC 51281715: Ampicillin benzathine

This classification denotes a penicillin antibiotic with the molecular structure C16H20N2.2C16H19N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E1TD7AM884 chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2r)-2-amino-2-phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2s,5r,6r)-, compd. with n,n'-bis(phenylmethyl)-1,2-ethanediamine (2:1), but more commonly known as ampicillin benzathine, which bears US NIH Compound Identifier 94447.

UNSPSC 51281715 Ampicillin benzathine is a Commodity code that captures pharmaceutical products purchased through state and local health procurement vehicles, though the recent opportunities block shows minimal direct activity under this specific code. The Illinois Department of Public Health and Seminole County, Florida appear in the available records, but neither opportunity directly involves ampicillin benzathine; the Illinois contract awarded to Chartwell Rx LLC covers Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets through an MMCAP Infuse piggyback arrangement, while the Seminole County IFB targets naloxone and drug deactivation systems. State and local health departments and county public health entities are the typical issuing bodies for pharmaceutical commodities at this tier, often leveraging cooperative purchasing consortia to aggregate volume and reduce cost.

The geographic activity visible in the source is limited to Illinois and Florida, with the Illinois Department of Public Health running a $2,999,999.11 multi-year piggyback contract through MMCAP Infuse (completed award, not an open solicitation) and Seminole County releasing an IFB with a July 26, 2023 deadline for 1,900 units of naloxone and 800 deactivation systems annually. The code shows little recent relevant activity directly tied to ampicillin benzathine procurement; business development professionals evaluating this Commodity should monitor state health department and county pharmaceutical aggregation notices, particularly those moving through cooperative purchasing vehicles such as MMCAP or state-specific group purchasing organizations, rather than expect routine single-product solicitations for this specific antibiotic formulation.